Form 4: Hologic Merger Completes, Executive Ownership Changes

Hologic, Inc. announces the completion of its merger with Hopper Parent Inc., resulting in significant changes to executive beneficial ownership and stock option holdings.

Summary

• Hologic, Inc. has completed its merger with Hopper Parent Inc. (Parent) and Hopper Merger Sub Inc. (Merger Sub).
• The merger resulted in Hologic becoming a wholly owned subsidiary of Parent.
• Each share of Hologic common stock was converted into $76.00 in cash and one contingent value right (CVR) potentially worth up to $3.00.
• Executive Martin D. Madaus's beneficial ownership of Hologic common stock has changed due to the merger.
• Outstanding stock options were either cancelled and converted into cash and CVRs, or cancelled for no consideration depending on their exercise price relative to the merger consideration.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it confirms the completion of a merger with a substantial cash payout and potential additional value through CVRs for shareholders and option holders.

Positives

• Shareholders received $76.00 per share in cash, representing a significant cash payout.
• Shareholders also received a contingent value right (CVR) for potential additional cash consideration of up to $3.00 per share.
• The merger provides a clear exit for shareholders at a specified cash price.

Negatives

• As a result of the merger, the reporting person no longer beneficially owns any shares of Hologic common stock.
• Stock options with exercise prices at or above the cash consideration plus $3.00 were cancelled for no value.

Risks

• The payment of the CVR is contingent on certain future events and may not be realized.
• The merger agreement was dated October 21, 2025, and the transaction closed on April 7, 2026, indicating a period of uncertainty during the merger process.

Future Outlook

The future outlook for the reporting person is no longer tied to Hologic's stock performance as they no longer beneficially own shares. The CVRs represent a potential future payout for former shareholders and option holders, contingent on specific conditions being met.

Management Comments

• The merger agreement was dated as of October 21, 2025.
• At the effective time of the Merger, each share of Hologic common stock was converted into the right to receive $76.00 per share in cash, without interest, and one contingent value right (CVR).

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a significant event in the life of a public company – a going-private transaction. Such transactions often involve substantial cash payouts to shareholders and the conversion or cancellation of equity awards, fundamentally altering the ownership structure and the reporting obligations of insiders.

Comparison to Industry Standards

• In typical going-private transactions, a premium is paid over the market price to incentivize shareholders. The $76.00 cash consideration plus a potential $3.00 CVR suggests a deal structure aimed at providing significant value realization for Hologic shareholders.
• The treatment of stock options, where those with exercise prices below the cash consideration are converted into cash and CVRs, is a standard practice in such mergers to ensure that in-the-money options are compensated.

Stakeholder Impact

• Shareholders: Receive $76.00 cash per share plus a potential CVR, providing a liquidity event.
• Option Holders: Outstanding options were converted into cash and/or CVRs, with the value dependent on the option's exercise price.
• Employees: Those holding RSUs or options received compensation as per the merger terms.
• Creditors: The company's debt obligations remain, now under new ownership.

Next Steps

• Shareholders and former option holders will await the determination of whether the conditions for the CVR payout are met.
• The reporting person will no longer be subject to Section 16 reporting requirements for Hologic common stock as they no longer beneficially own any.

Key Dates

Keywords

Hologic, Merger, Hopper Parent Inc., Hopper Merger Sub Inc., SEC Form 4, Beneficial Ownership, Stock Options, Contingent Value Right, Martin D. Madaus, M&A